Archive for February 2018
Matthew McMahon, PhD
Dr. McMahon leads the Office of Translational Alliances and Coordination to enable the development and commercialization of research discoveries funded by the Heart, Lung and Blood Institute. His office manages NHLBI’s $100 million/year Small Business Program and a national network of six proof-of-concept centers that support the translation of academic discoveries into product development projects.…
Read MoreKenneth Bahk, PhD
Prior to Three Lakes Partners, an impact investment fund focused on improving the lives of those with IPF, Ken has served in key investment and management roles for over $1B in exits. He has also served in leadership positions for professional organizations including the American Association for Clinical Chemistry, Association for Molecular Pathology and the…
Read MoreJeffrey Goldstein
Jeff Goldstein is a double lung transplant recipient (2003) and the Founding Member and President of the Lung Transplant Foundation (LTF). The LTF’s mission is to improve the lives of lung transplant recipients and is particularly interested in the development of therapies and technologies to treat BOS and rejection. Mr. Goldstein’s background is in business…
Read MoreTimothy Watkins, MD, MSc
Tim Watkins is a Director of Clinical Research in Respiratory/Inflammation Therapeutics at Gilead Sciences. He has over a decade of experience in the biomedical and biopharmaceutical sectors, with clinical research spanning ARDS, trauma, sepsis, viral pneumonia and other aspects of inflammatory and respiratory diseases. At Gilead, Tim is responsible for the clinical development of drug…
Read MoreNicholas Simon
Nicholas Simon has been a managing director of Clarus Ventures since the firm’s inception in 2005. Prior to Clarus, he was a general partner at MPM Capital, a healthcare venture capital firm. He has more than 30 years of operating and investment experience in the biopharmaceutical industry, including serving as vice president of business and…
Read MoreStephen Beckman
Over the past 25 years, there have been consistent themes that represent the performance of Stephen Beckman. It starts with the desire to exceed expectations, create disruptive change to build growing and sustainable business, and leading a culture where every employee thrives regardless of level or role. • A career approach that operates against three…
Read MoreCecilia Gonzalo
Ms. Gonzalo is a Partner at Oberland Capital, a private investment firm with over $1.2 billion in capital commitments since inception, that is focused exclusively on investing in the global healthcare industry. Prior to joining Oberland, she was a Managing Director at Vatera Healthcare Partners where she focused on venture capital and private equity investments…
Read MoreDennis Wahr, MD
Dennis Wahr, MD is the CEO of Nuvaira which is developing a unique minimally invasive bronchoscopic treatment for patients with chronic obstructive lung disease called Targeted Lung Denervation (TLD). Prior to joining Nuvaira, Dr. Wahr co-founded Lutonix in 2007 and served as its President and CEO until CR Bard acquired the company in December 2011.…
Read More